Zusammenfassung
Die Behandlung von Kindern und Jugendlichen mit chronisch entzündlichen Darmerkrankungen (CED) ist aufgrund einer schmalen wissenschaftlichen Basis für Therapieentscheidungen nach wie vor problematisch. Daten aus Studien bei Erwachsenen sind mit Vorbehalt zu werten. Biologika (TNF-α-Blocker) haben die CED-Therapie bereichert. Studiendaten zeigen bei Kindern einen steroidsparenden und das Wachstum optimierenden Effekt. Bei Versagen einer Standardtherapie sowie bei extraintestinalem Befall und Fisteln werden TNF-α-Blocker zunehmend primär oder früh im Therapiekonzept eingesetzt. Bei Kindern mit schwerer Colitis ulcerosa sind TNF-α-Blocker trotz fehlender Zulassung eine Alternative zu bisherigen Immunsuppressiva.
Abstract
The treatment of children and adolescents with chronic inflammatory intestinal diseases is still problematic because of a narrow scientific basis for therapeutic decision-making. Data from studies involving adults must be evaluated with caution. Biologics, such as TNF-α blockers have been approved for the induction and maintenance of remission in moderate-to-severe pediatric Crohn’s disease that is unresponsive to conventional therapy. Data from studies on children show a steroid-saving and growth optimizing effect. Regularly scheduled maintenance therapy is recommended. Inflixmab is also a therapeutic alternative in children with severe ulcerative colitis. Adalimumab may be used in cases of side-effects or loss of response.
Literatur
Beaugerie L, Brousse N, Bouvier AM, CESAME Study Group et al (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374: 1617–1625
Borelli O, Bascietto C, Viola F (2004) Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 36: 342–347
Buderus S (2004) Chronisch-entzündliche Darmerkrankungen: Medikamentöse Therapie im Kindes- und Jugendalter. Monatsschr Kinderheilk 152: 133–44
Colombel JF, Sandborn WJ, Reinisch W, SONIC Study Group et al (2010) Infliximab, Azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362: 1383–1395
Crandall W, Hyams J, Kugathasan S et al (2009) Infliximab therapy in children with concurrent perianal Crohn disease: Observations from REACH. J Pediatr Gastroenterol Nutr 49: 183–190
Cucchiara S, Latiano A, Palmieri O et al (2007) Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 171–179
Carpi JM de, Pociello N, Varea V (2010) Long-term efficacy of adalimumab in paediatric Crohn‘ disease patients naïve to other anti-TNF therapies. J Crohn’s Colitis 4: 594–598
Zoten E de, Mamula P (2008) What are the guidelines for using biologics in pediatric patients? Inflamm Bowel Dis 14: S259–S261
Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M (2005) Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 11: 213–218
Escher JC, Taminiau JAJM, Nieuwenhuis EES, Buller HA, Grand RJ (2003) Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 9: 34–58
Hyams J, Crandall W, Kugathasan S, REACH Study Group et al (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 132: 863–873
Hyams J, Lerer T, Griffiths A, Pfefferkorn M et al (2009) Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis 15: 816–822
Hyams J, Lerer T, Griffiths A, Pfefferkorn M et al (2010) Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 105: 1430–1436
Hyams J, Walters TD, Crandall W et al (2011) Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in childen: REACH open-label extension. Curr Med Res Opin 27: 651–662
Kardorff R, Radke M (2008) Chronisch entzündliche Darmerkrankungen. Pädiatrie 3 („up2date“): 13–44
Mahadevan U, Cucchiara S, Hyams J et al (2011) The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organization. Am J Gastroenterol 206: 214–223
McGinnis JK, Murray KF (2008) Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol 42: 875–879
Pfefferkorn M, Burke G, Griffith A et al (2009) Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 48: 168–174
Rosh JR, Gross T, Mamula P (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 13: 1024–1030
Rosh JR, Markowitz J, Goli SR (2008) Retrospective evaluation of the safety and effect of adalimumab therapy (reseat) in pediatric Crohn’s disease. Gastroenterology 134: A657
Ruemmele FM, Lachaux A, Cézard J-P, Morali A et al (2009) Efficacy of infliximab in pediatric Crohn’s disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 15: 388–394
Ruemmele FM (2010) Pediatric inflammatory bowel diseases: coming of age. Curr Opin Gastroenterol 26: 332–336
Russell RK, Wilson ML, Loganathan S et al (2011) A British Society of Peadiatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 33: 946–953
Rutgeerts P, Feagan BG, Lichtenstein GR (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126: 402–413
Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS (2010) Infliximab improves inflammation and anthropometric measures in pediatric Crohn’s disease. J Gastroenterol Hepatol 25: 810–816
Timmer A, Behrens R, Buderus S et al (2011) Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA german-language pediatric inflammatory bowel disease registry. J Pediatr 158: 467–473
Turner D, Griffith AM (2011) Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 17: 440–449
Vermeire S, Noman M, Assche GV van et al (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 56: 1226–1231
Walters TD, Gilman AR, Griffiths AM (2007) Linear growth improves during Infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis 13: 424–430
Wynands J, Belbouab R, Candon S et al (2008) 12-month follow-up after succesful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 46: 293–298
Wyneski MJ, Green A, Kay M et al (2008) Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 47: 19–25
Interessenkonflikt
Der Autor weist auf folgende Beziehungen hin: Mitglied im Advisory Board für chronisch entzündliche Darmerkrankungen im Kindesalter der Fa. MSD sowie Referententätigkeit für die Firmen MSD, Falk und Abbott.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Radke, M. Behandlung chronisch entzündlicher Darmerkrankungen bei Kindern und Jugendlichen. Gastroenterologe 6, 486–495 (2011). https://doi.org/10.1007/s11377-010-0513-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11377-010-0513-x